Journal article
The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary
Abstract
Questions: 1. What is the role of trastuzumab in the treatment of women with HER2/neu-overexpressing metastatic breast cancer? 2. What are the most effective methods of assessing HER2/neu status? Perspectives: Trastuzumab (Herceptin®) is a monoclonal antibody approved for use in Canada since August 1999. The Breast Cancer Disease Site Group (DSG) of Cancer Care Ontario's Practice Guidelines Initiative examined the role of trastuzumab in the …
Authors
Crump M; O'Malley F; Pritchard K; Levine M; Johnson M
Journal
Current Oncology, Vol. 7, No. 4, pp. 242–251
Publication Date
January 1, 2000